Liponex Response to TSX Review

    OTTAWA, Feb. 1 /CNW/ - Liponex Inc (TSX:LPX), announced today that the
TSX communicated on January 30, 2008, that it is reviewing the eligibility of
the common shares of Liponex for continued listing on the TSX. In particular,
the TSX review indicated that (i) the price of the company's securities has
been so reduced as not to warrant continued listing; (ii) the market value of
the listed shares has been less than $3.0 million for 30 consecutive trading
days; and (iii) there has been a substantial change to the business. Liponex
has been granted until May 29, 2008 to regain compliance with these
    Liponex and its representatives are currently in discussion with the TSX
regarding this matter. Should the TSX decide to de-list the shares of Liponex,
the shares may qualify for listing on the TSX Venture Exchange or NEX.
    As previously announced, on January 30, 2008, Liponex entered into a
non-binding letter of intent with ImaSight Inc. regarding a proposed business
combination. There can be no assurance that any binding agreement will result
from this or that any transaction will be completed that would put the Company
in a position to meet the TSX listing requirements.

    About Liponex and CRD5

    Liponex is a Biopharmaceutical development company developing natural
source products for the treatment of cholesterol and metabolic disease. CRD5,
its lead product, has undergone a number of human clinical trials under
approval of Health Canada's Natural Health Products Directorate with a primary
goal of increasing HDL "good cholesterol".

    This news release contains certain "forward-looking statements" and
"forward-looking information" which may include but is not limited to
statements in respect of Liponex's future financial position or operations.
Words like "believe", "intend", "may", "expect", "anticipate", "plan",
"should" and other similar expressions are forward-looking statements that
involve a number of risks and uncertainties. By their nature, forward-looking
statements involve numerous factors, assumptions and estimates. Some but not
all of the factors that could cause actual results to differ materially from
those projected in our forward-looking statements include among others:

    -   the failure to sign a definitive agreement regarding the potential
        combination of Liponex and ImaSight;
    -   failure to receive required transaction approvals from Liponex's and
        ImaSight's shareholders;
    -   the ability of Liponex and ImaSight to satisfy all of the closing
        conditions to complete the transaction;
    -   failure to receive necessary stock exchange listing approvals;
    -   other risk factors identified from time to time in Liponex's
        securities regulatory filings.

    For a further description of the principal risks affecting Liponex, see
Liponex's regulatory filings at These factors should be
considered carefully and readers are cautioned not to place undue reliance on
such forward looking statements. Although Liponex has attempted to identify
important risks, uncertainties and other factors that could cause actual
results or events to differ materially from those expressed or implied in the
forward looking statements, there may be other factors that cause actual
results or events to differ from those expressed or implied in the
forward-looking statements. All forward-looking statements are qualified in
their entirety by this cautionary statement and Liponex undertakes no
obligation to revise or update any forward-looking statements as a result of
new information, future events or otherwise after the date hereof.

    The TSX does not accept responsibility for the adequacy or accuracy of
    this release.

    %SEDAR: 00022196E

For further information:

For further information: Investor Relations, Michael Moore, The Equicom
Group Inc., (416) 815-0700 ext. 241,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890